Sunday, February 26, 2017 6:12:30 PM
GERN (T/$5) Geron Corp, biotech... lead candidate, imetelstat, appears to have an important advantage over the leading treatment (Jakafi) for a rare form of blood cancer known as myelofibrosis, a disorder marked by overactive blood cell production in bone marrow. In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage.
Daily
60minute
GERN
Daily
60minute
GERN
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
